Recently, several distinguished Sheba clinicians were impressed by the tool’s capabilities. The group, which included Dr. Vera Sorin, Dr. Eyal Klang, Dr. Miri Sklair-Levy, Prof. Douglas B. Zippel, and Dr. Israel Cohen, decided to conduct a study dedicated to exploring some of its potential applications in medicine with the aim of improving patient care.
The study focused on the software’s usefulness as a supportive tool for breast tumor decision-making, comparing its suggestions to those of a breast cancer board. Findings, which were published in Nature under the title “Advancements in Disease Treatment: A Multidisciplinary Approach,” marked a significant milestone.
The output generated by ChatGPT underwent a thorough evaluation in three key areas: summarization, recommendation, and explanation, with ChatGPT’s suggestions aligning with the tumor board’s decisions in seven out of ten cases (70%).
Accordingly, the tool’s potential in accelerating and improving patient care is evident, providing clinical information in a summarized and concise way while offering clear explanations for its recommendations in a way that promises to empower medical practitioners to make calculated decisions in the best interests of their patients.
Sheba takes pride in being at the forefront of healthcare innovation, leading the way in integrating AI-driven solutions into clinical workflows. While this latest innovation still requires further study, we look forward to employing it in accelerating the diagnostic process.